Xenon Pharmaceuticals (XENE) is back in focus after presenting Phase 3 X-TOLE2 data for azetukalner in adults with focal onset seizures, supported by long term X-TOLE extension and real world no titration feedback.

The latest clinical update has arrived after a strong few quarters for the stock, with a 36.87% 90 day share price return and a 46.63% 1 year total shareholder return that suggest momentum has been building around Xenon’s lead epilepsy program.

If this kind of neurology and epilepsy story interests you, it could be a good time to look across the broader healthcare AI opportunity set using our curated list of 33 healthcare AI stocks.

With Xenon trading at US$56.13, a 36.87% 90 day return and a 46.63% 1 year total return already on the board, is the market still behind the story here or is future growth already fully priced in?

Most Popular Narrative: 43.9% Undervalued

Against a last close of $56.13, the most followed Xenon narrative points to a fair value of $100.00, which is a wide gap to current pricing.

A broad ion channel pipeline that includes Nav1.7, Kv7 and Nav1.1 programs now in or approaching clinical stages creates multiple potential follow on products in epilepsy and pain, which, over time, can diversify cash flows and reduce reliance on a single asset for future earnings growth.

Want to see what sits behind that projected ramp in cash flows and earnings power? The narrative leans on aggressive revenue build, margin shifts and a punchy future earnings multiple.

Result: Fair Value of $100.00 (UNDERVALUED)

However, keep in mind that azetukalner setbacks in Phase 3 or slower adoption in crowded epilepsy and mood markets could quickly challenge this undervalued narrative.

Next Steps

With sentiment split between the upside of Xenon’s pipeline and the risks around execution, now is a good time to look at the evidence yourself. You can start with the 3 key rewards and 3 important warning signs.

Looking for more investment ideas?

If you are serious about putting this update to work, now is the moment to broaden your watchlist with a few focused sets of stock ideas.

• Target cash rich balance sheets and steadier fundamentals by scanning companies in the solid balance sheet and fundamentals stocks screener (45 results).
• Hunt for companies where expectations and price may not fully align with business quality using the 51 high quality undervalued stocks.
• Spot earlier stage opportunities with room for market attention to build by checking the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.